ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Update

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 415,800 shares, a growth of 61.2% from the February 13th total of 257,900 shares. Based on an average trading volume of 575,900 shares, the short-interest ratio is presently 0.7 days. Currently, 3.7% of the company’s shares are sold short.

Institutional Trading of ABVC BioPharma

A hedge fund recently raised its stake in ABVC BioPharma stock. Avantax Planning Partners Inc. grew its position in ABVC BioPharma, Inc. (NASDAQ:ABVC) by 269.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 143,968 shares of the company’s stock after buying an additional 104,968 shares during the period. Avantax Planning Partners Inc. owned approximately 1.11% of ABVC BioPharma worth $85,000 at the end of the most recent quarter. 11.38% of the stock is owned by institutional investors and hedge funds.

ABVC BioPharma Stock Performance

ABVC opened at $0.65 on Friday. The company has a fifty day moving average price of $0.57 and a two-hundred day moving average price of $0.58. ABVC BioPharma has a 52 week low of $0.40 and a 52 week high of $1.73. The firm has a market capitalization of $8.38 million, a PE ratio of -0.75 and a beta of 0.67.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.